TECH
Bio-Techne Corporation (S&P 500)
Healthcare — Biotechnology
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. Its Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Price History
Fundamentals
| Market Cap | $11.35B |
| P/E Ratio (TTM) | 62.41 |
| Forward P/E | 31.31 |
| EPS (TTM) | $1.16 |
| Dividend Yield | 0.44% |
| Profit Margin | 14.97% |
| Revenue Growth | 1.30% |
| ROE | 9.03% |
| Debt/Equity | 13.71 |
| Recommendation | Hold 2.8 |
| Analyst Target | $70.50 |
| Analysts | 10 |
| Next Earnings | Aug 12, 2026 BMO |
| Indexes | S&P 500 |
Technical Indicators
| RSI (14) | 63.5 |
| Beta | 1.28 |
| SMA 20 | $72.39 |
| SMA 40 | $72.34 |
| 52-Week High | $72.69 |
| 52-Week Low | $43.20 |
| 50-Day Avg | $72.25 |
| 200-Day Avg | $61.90 |
| Avg Volume | $3.34M |
| Volume | $2.71M |
Performance Analysis
NEUTRALTECH presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Oct 01, 2026 21:01 UTC
Back to Screener Export Report